Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Durata Therapeutics, Inc.

Durata Therapeutics, established in 2009 in Morristown, New Jersey, is a clinical development stage pharmaceutical company which focuses on the treatment of infectious diseases. The company acquired dalbavancin, a long-acting semisynthetic lipoglycopeptide antibiotic, from Pfizer in December 2009. Durata has initiated two Phase III studies of dalbavancin for intravenous (IV) treatment of acute bacterial skin and skin structure infections. In 2012, the company moved its global headquarters from Morristown to Chicago in a deal with $2 million in tax credits. In October 2014 Durata was acquired by Actavis for about $675 million.


Investment goal date:
Dividends reinvested
Durata Therapeutics, Inc. DRTX report
Period
Date
Adjusted Actuals EPS
GAAP EPS
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Major Shareholders
Name Relationship
Total Shares
Holding stocks
TREU JESSE I
0.0800% (22306)
BLAIR JAMES C
0.0800% (22306)
HORNER GEORGE F III
0.2700% (71728)
DRTX /
GOLDSTEIN DOV A MD
11.6900% (3130824)
VITULLO NICOLE
0.0800% (22306)
DOVEY BRIAN H
0.0800% (22306)
SCHOEMAKER KATHLEEN K
0.0800% (22306)
HEALY JAMES
8.4800% (2271330)
HUNT RONALD
11.3100% (3028439)
DRTX / RLYP /
Ahrens Brenton Karl
0.0200% (5034)
DRTX /
Halak Brian K
0.0800% (22306)
% ()